DIAMOND: High Virologic Suppression Rates Achieved Following Rapid Initiation of DRV/COBI/FTC/TAF Regardless of Baseline HIV-1 RNA Level or CD4+ Cell Count

IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
No patient met criteria for protocol-defined virologic failure or discontinued for lack of efficacy through Week 48.
Format: Microsoft PowerPoint (.ppt)
File Size: 209 KB
Released: October 29, 2019

Acknowledgements

Provided by USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

ANDES: Wk 48 safety and efficacy of generic darunavir/ritonavir + lamivudine for initial HIV treatment, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

Expert summaries of ART treatment initiation in treatment-naive PWH, including rapid and same-day ART starts, from Clinical Care Options (CCO)

Babafemi Taiwo, MBBS
Program Director
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Released: August 4, 2022

Expert summaries of the HIV care cascade and strategies and interventions to improve linkage to care for PWH, from Clinical Care Options (CCO)

Babafemi Taiwo, MBBS
Program Director
Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD
Released: August 3, 2022

Week 48 results from ALLIANCE study of BIC/FTC/TAF vs DTG plus FTC/TDF for HIV/HBV coinfection, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 3, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings